We are live on ! Find out more
ANAB icon

AnaptysBio

121 hedge funds and large institutions have $460M invested in AnaptysBio in 2019 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 47 increasing their positions, 19 reducing their positions, and 38 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more funds holding in top 10

Funds holding in top 10: 1 → 3 (+2)

147% more repeat investments, than reductions

Existing positions increased: 47 | Existing positions reduced: 19

2% more funds holding

Funds holding: 119 → 121 (+2)

5% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 38

3.13% less ownership

Funds ownership: 107.36% → 104.23% (-3.1%)

28% less capital inflows, than outflows

Capital inflows: $344M | Capital outflows: $477M

32% less call options, than puts

Call options by funds: $7.84M | Put options by funds: $11.5M

Holders
121
Holders Change
+2
Holders Change %
+1.68%
% of All Funds
2.37%
Holding in Top 10
3
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+200%
% of All Funds
0.06%
New
40
Increased
47
Reduced
19
Closed
38
Calls
$7.84​M
Puts
$11.5​M
Net Calls
-⁠$3.64​M
Net Calls Change
-⁠$5.41​M

ANAB Hedge Fund Activity: Q4 2019 in Review

121 of the 5,095 institutional investors tracked by Wall St. Rank reported a position in AnaptysBio (ANAB) for Q4 2019, worth a combined $460M — down 55% from $1.02B a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new ANAB positions and 38 closed out — a net gain of 2 holders — while 47 added to existing stakes and 19 trimmed.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $46.5M. The largest seller was Adage Capital Partners, exiting entirely with an estimated $94.3M sold.

  • 121 institutional investors held AnaptysBio (ANAB) as of Q4 2019, up from 119 in Q3 2019.
  • Funds reported $460M of AnaptysBio stock for Q4 2019, down 55% quarter-over-quarter.
  • 40 funds opened new AnaptysBio positions in Q4 2019 and 38 closed out, a net change of +2 holders.
  • The largest AnaptysBio buyer in Q4 2019 was EcoR1 Capital, an estimated $46.5M added.
  • The largest AnaptysBio seller in Q4 2019 was Adage Capital Partners, an estimated $94.3M sold.

Based on aggregated 13F filings for Q4 2019.